SciELO - Scientific Electronic Library Online

 
vol.40 número3Uso de métodos anticonceptivos de alta eficacia posterior a la interrupción voluntaria del embarazo en Profamilia, 2015-2020 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Facultad Nacional de Salud Pública

versión impresa ISSN 0120-386Xversión On-line ISSN 2256-3334

Resumen

SILVA-AYCAGUER, Luis Carlos  y  BLOCH-SILVA, Andrés. Reflexiones acerca de las cambiantes narrativas sobre las vacunas contra la covid-19. Rev. Fac. Nac. Salud Pública [online]. 2022, vol.40, n.3, e07.  Epub 31-Mayo-2023. ISSN 0120-386X.  https://doi.org/10.17533/udea.rfnsp.e349338.

We set out to discern to what extent the media strategies adopted around the vaccines against covid-19 during the first 15 months since the beginning of their application can be considered as a legitimate and coherent contributions to a better understanding about their performance and to what extent the elaborated discourses could respond to the economic interests of the corporations’ elites. Once the most relevant elements that have shaped the predominant narratives from the moment the vaccines were conceived were compiled, several anomalies were identified that were to a greater or lesser extent invisibilized in the process of their approval and the results of their application. The most significant of these concern the handling of definitions, non-compliance with commitments and conflicts of interest that compromise the actions of vaccine marketing companies and regulatory bodies. Many elements related to corporative interests have influenced the narrative concerning vaccines. Among those that require a resignification are: their real preventive capacity against contagions, serious diseases and deaths, their efficacy against new variants, the duration of the immunity they confer, their side effects, the synergic role of acquired immunity, and the resources used by the companies to achieve a virtually market monopolistic predominance.

Palabras clave : COVID-19 vaccines; Efficacy; Controlled clinical trial; Conflict of interest; Marketing.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )